retatrutide obesity trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio Retatrutide just delivered the most

Lilly spokesperson Kristiane Silva Bello said her company was "deeply concerned" about "serious health risks" from compounded drugs that "should not be on the market." Yet marketed they are

The information presented here is based on available preclinical and clinical research and shouldn't be used as a substitute for professional medical guidance

Initial targets included compounding pharmacies like Strive and Empower, which Lilly accused of continuing to produce mass-manufactured tirzepatide while falsely marketing it as "personalized" medication

Rev Bras Cinc Solo

10.1254/jphs.fp0072161 [DOI] [PubMed] [Google Scholar] Kolovrat M., Gojkovic S., Krezic I., Malekinusic D., Vrdoljak B., Kasnik Kovac K., et al

Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children